Checkpoint Therapeutics Overview
- Founded
-
2014
- Status
-
Public
- Employees
-
18
- Stock Symbol
-
CKPT
- Investments
-
1
- Share Price
-
$3.82
- (As of Monday Closing)
Checkpoint Therapeutics General Information
Description
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP).
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
- 95 Sawyer Road
- Suite 110
- Waltham, MA 02453
- United States
+1 (781) 000-0000
Checkpoint Therapeutics Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.82 | $3.72 | $3.45 - $19.00 | $42.5M | 11.4M | 211K | -$8.70 |
Checkpoint Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 65,310 | 200,331 | 137,862 | 79,166 |
| Revenue | 134 | 268 | 1,069 | 1,708 |
| EBITDA | (71,459) | (56,723) | (23,201) | (24,850) |
| Net Income | (71,358) | (56,670) | (23,081) | (24,714) |
| Total Assets | 21,620 | 55,728 | 42,596 | 26,966 |
| Total Debt | 0 | 0 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Checkpoint Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Checkpoint Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisiti
Biotechnology
Waltham, MA
18
As of 2022
00000
00000000000
00000
00000
nim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea comm
0000000000000
Thousand Oaks, CA
00000
As of 0000
00.000
000000000000
00.000
000000
irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nul
0000 000000000
Hennigsdorf, Germany
00
As of 0000
000.00
0000000000 0
000.00
Add Comparison
Checkpoint Therapeutics Competitors (26)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Amgen | Formerly PE-Backed | Thousand Oaks, CA | 00000 | 00.000 | 000000000000 | 00.000 |
| 000000000 00000000 | Venture Capital-Backed | Hennigsdorf, Germany | 00 | 000.00 | 0000000000 0 | 000.00 |
| 000000 | Formerly VC-backed | Wilmington, DE | 0000 | 00000000000 | ||
| 000000 00000000000 | Corporation | New York, NY | 00 | 00000 | 000000000 | 00000 |
| 000000 00000000000 | Venture Capital-Backed | New York, NY | 000.00 | 00000000000 | 000.00 |
Checkpoint Therapeutics Patents
Checkpoint Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2017290709-A1 | Pd-l1-specific antibodies and methods of using the same | Pending | 29-Jun-2016 | 00000000000 | |
| CA-3027204-A1 | Pd-l1-specific antibodies and methods of using the same | Pending | 29-Jun-2016 | 00000000000 | |
| EP-3478723-A2 | Pd-l1-specific antibodies and methods of using the same | Pending | 29-Jun-2016 | 00000000000 | |
| EP-3478723-A4 | Pd-l1-specific antibodies and methods of using the same | Pending | 29-Jun-2016 | 00000000000 | 0 |
| JP-2022120008-A | Pd-l1-specific antibody and method of using the same | Pending | 29-Jun-2016 | C07K16/2827 |
Checkpoint Therapeutics Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| James Oliviero III | Chief Executive Officer & Board Member | ||
| Garrett Gray | Chief Financial Officer |
Checkpoint Therapeutics Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000 00000000 000 | Checkpoint Therapeutics | Chief Executive Officer & Board Member | 000 0000 |
| 0000000 00000 00 | Self | Chairman & Board Member | 000 0000 |
| 0000 0000000000 | Self | Board Member | 000 0000 |
Checkpoint Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Checkpoint Therapeutics Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000000 (00 | 000000000 | Buildings and Property |
Checkpoint Therapeutics ESG
Risk Overview
Risk Rating
Updated April, 01, 2021
47.19 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
0.000
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 14,042
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 947
Rank
00.00
Percentile
Pharmaceuticals
Subindustry
00 of 452
Rank
00.00
Percentile
